- Home
- APGE vs IOVA Comparison
APGE vs IOVA Comparison
Compare APGE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- IOVA
- Stock Information
- Founded
- APGE 2022
- IOVA 2007
- Country
- APGE United States
- IOVA United States
- Employees
- APGE N/A
- IOVA N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APGE Health Care
- IOVA Health Care
- Exchange
- APGE Nasdaq
- IOVA Nasdaq
- Market Cap
- APGE 3.0B
- IOVA 2.6B
- IPO Year
- APGE 2023
- IOVA N/A
- Fundamental
- Price
- APGE $48.46
- IOVA $7.75
- Analyst Decision
- APGE Strong Buy
- IOVA Strong Buy
- Analyst Count
- APGE 6
- IOVA 9
- Target Price
- APGE $75.40
- IOVA $23.33
- AVG Volume (30 Days)
- APGE 588.6K
- IOVA 5.4M
- Earning Date
- APGE 11-12-2024
- IOVA 11-07-2024
- Dividend Yield
- APGE N/A
- IOVA N/A
- EPS Growth
- APGE N/A
- IOVA N/A
- EPS
- APGE N/A
- IOVA N/A
- Revenue
- APGE N/A
- IOVA $90,858,000.00
- Revenue This Year
- APGE N/A
- IOVA $13,758.71
- Revenue Next Year
- APGE N/A
- IOVA $171.64
- P/E Ratio
- APGE N/A
- IOVA N/A
- Revenue Growth
- APGE N/A
- IOVA 12751.20
- 52 Week Low
- APGE $22.20
- IOVA $6.70
- 52 Week High
- APGE $72.29
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- APGE 47.85
- IOVA 34.10
- Support Level
- APGE $41.85
- IOVA $7.64
- Resistance Level
- APGE $48.27
- IOVA $8.14
- Average True Range (ATR)
- APGE 3.56
- IOVA 0.36
- MACD
- APGE 0.31
- IOVA -0.07
- Stochastic Oscillator
- APGE 47.51
- IOVA 4.26
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.